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Abstract 
We isolated revertant and resistant clones from multidrug-resistant K562/ADM cells and evaluated the expression of P-glycoprotein 
and the DNA copy number of MDRI. The 9 revertant clones contained 2- to 26-fold DNA copies of MDRI ; however, they expressed an 
extensively decreased P-glycoprotein compared with K562/ADM, while the 10 multidrug-resistant clones contained 4- to 48-fold DNA 
copies, and the expression level of P-glycoprotein was dependent on the copy number of MDRI DNA. The decreased expression of 
P-glycoprotein the revertants was not due only to the loss of the copy number of MDRI DNA. 
To elucidate the mechanism of P-glycoprotein expression decrease in the revertants, a revertant clone (R1-5) was fused with a 
multidrug-resistant clone (A2-1) or with a drug-sensitive clone isolated from K562. Compared with K562 clone, the A2-1 contained 
32-fold MDR1 DNA copies and showed 131-fold resistance to Adriamycin. The revertant clone R1-5 contained 26-fold MDR1 DNA 
copies but expressed only 5% the P-glycoprotein of A2-1 cells and showed only 2-fold resistance to Adriamycin. For selection of 
intraspecific hybrids, a neomycin-resistant or a blasticidin S-resistant gene was introduced into clones by electroporation f pSV2neo or 
pSV2bsr. The introduction of these resistant genes did not alter the copy number or expression of MDR1 in the clones. Hybrid cells 
between R1-5bsr and A2-1neo were found to express 136 _+ 15% of the P-glycoprotein of A2-1 cells evaluated by quantitative flow 
cytometry. These hybrid cells contained 41- to 48-fold MDR1 copies and showed the multidrug-resistant phenotype, such as decrease of 
rhodamine123 accumulation and 120- to 210-fold resistance to Adriamycin (compared with K562), indicating that the 'silent' MDRI 
genes in the revertant clone R1-5 were activated by cell fusion with an MDR clone. R1-5bsr × K562neo hybrids were found to contain 8- 
to I l-fold MDR1 copies and there was no increase in P-glycoprotein expression as compared with RI-5. 
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1. Introduction 
One of the serious obstacles to optimal cancer chemo- 
therapy is the drug-resistant tumor cells that develop dur- 
ing treatment [1-3]. Multidrug resistance (MDR) is charac- 
terized by cross-resistance to functionally and structurally 
unrelated rugs, including Vinca alkaloids, anthracyclines 
and epipodophylotoxins. Concomitantly, overexpression f
MDR1 gene product (P-glycoprotein) on the surface mem- 
Abbreviations: MDR, multidrug resistance; neo, neomycin; bsr, blas- 
ticidin S; Rh123, rhodamine 123; XTT, [2,3-bis(2-methoxy-4-nitro-5- 
sulfophenyl)-5-[(phenylamino)-carbonyl]-2 H-tetrazolium hydroxide]; 
IC50, concentration f drug producing 50% cell growth inhibition. 
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brane is usually observed with the emergence of MDR. 
The mechanism of this resistance is a decrease in accumu- 
lation and retention of the antitumor agents, which is 
mediated by a drug efflux pump, P-glycoprotein [4-6]. 
P-glycoprotein is a member of the super family of ABC 
transporters that have highly conserved ATP-binding cas- 
settes and utilize the energy of ATP hydrolysis to pump 
substrate across the membrane against a concentration 
gradient [7]. K562 cells express a low level of MDR1 
mRNA, detected by polymerase chain reaction, but P- 
glycoprotein was not detected on their cell surface [8]. 
Adriamycin-resistant K562/ADM cells established from 
K562 cells showed the typical MDR phenotype, i.e., multi- 
ple copies of MDR1 and a high level of P-glycoprotein on 
the cell surface [9,10]. Several revertants from MDR cells 
have been reported, in which a decrease in MDR1 mRNA 
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expression was accompanied by loss of the amplified gene 
copies [11,12]. While we have isolated from K562/ADM 
cells two revertant clones ~that contained multiple copies of 
MDRI gene but with markedly decreased expression of 
MDRI mRNA [ 13]. 
Somatic cell hybridization provides a unique system to 
analyze gene interaction. Ling and Baker [14] showed that 
the MDR phenotype was dominantly expressed in CHO 
hybrids. In this report, we investigated the copy number of 
MDRI and the expression of P-glycoprotein a revertant 
clone fused with a MDR or a drug-sensitive clone. The 
expression level of MDRI in the hybrids was examined by 
quantitative flow cytometry to find whether 'silent' multi- 
ple MDRI genes of reverlant cells could be activated or 
whether activated multiple MDRI genes derived from 
MDR cells could be suppressed in the somatic ell hybrids. 
sulfate, 10% 2-mercaptoethanol, 125 mM Tris-HCl, pH 
6.8), boiled for 10 min, and the samples containing 10 /xg 
of protein were resolved by sodium dodecyl sulfate-poly- 
acrylamide gel electrophoresis. The proteins were trans- 
ferred by electroblotting to nitrocellulose. After incubation 
of the nitrocellulose in Block Ace (Yukijirushi, Tokyo) for 
5 h, the nitrocellulose was incubated with anti-P-glyco- 
protein antibody C219 (Centocor, Inc., Malvern, PA) for 1 
h in calcium-free phosphate-buffered saline (PBS) contain- 
ing 0.05% Tween 20 and sequentially reacted for 1 h with 
~_~5 I-labeled goat anti-mouse IgG (ICN Biochemicals, Costa 
Mesa, CA; 0.76 MBq/mg). The nitrocellulose was dried 
and exposed to Kodak AR film. Autoradiograms were 
scanned by Sharp JX-320M and analyzed using the IM- 
AGE software program on a Macintosh computer. 
2.4. Introduction of resistant marker genes 
2. Materials and methods 
2.1. Cell culture 
K562, A2-1 and R1-5 were transfected by electropora- 
tion with pSV2neo [16] or pSV2bsr plasmid [17]. Cells 
(2 x 107/ml) were washed twice with PBS, resuspended 
The revertant clones were isolated from K562/ADM 
cells, as previously described [9]; MDR clones were also 
isolated from K562/ADM cells. After isolation, clones 
were expanded, and frozen in the liquid nitrogen until 
needed. There was less than a 10% decrease of copy 
number in MDRI DNA and of P-glycoprotein expression 
in MDR clones A2-1, A2-1 neo and A2-1 bsr maintained in
drug free medium at least for 60 days. Neither was there 
significant decrease of copy number of MDRI DNA and 
of P-glycoprotein expression in revertant clones R 1-5 and 
RI-5bsr at least for 60 days. Cells were grown in RPMI- 
1640 medium supplemented with 5% fetal calf serum 
(Fcs). 
2.2. DNA dot blot analysis 
Genomic DNA was isolated, and transferred to nitro- 
cellulose membranes using a Bio-Rad dot apparatus. The 
filters were dried, baked at 80°C for 2 h, and hybridized 
with a S2P-labeled MDR1 probe. After hybridization for 
16 h at 65°C in hybridization solution [0.75 M NaCI, 2 
mM ethylenediaminetetraacetic acid (EDTA), 1 x 
Denhardt's olution, 0.1% sodium dodecyl sulfate, and 50 
mM Tris(hydroxymethyl) aminomethane hydrochloride 
(pH 8.0)], the filter was washed three times at 65°C for 30 
rain in 2 X standard saline citrate (SSC) [1 X SSC: 0.15 M 
NaCl, 0.015 M sodium citrate (pH 7.2)] and twice in 
0.5 X SSC and then autoradiographed. 
2.3. lmmunoblot analysis 
The cell membrane was prepared, as described previ- 
ously [15]. The membrane was solubilized by adding an 
equal volume of gel samr, le buffer (4% sodium dodecyl 
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Fig. I. Relative copy number of MDR1 in K562. A2-1, RI-5. K562neo, 
A2-lneo, A2-lbsr, and R I-5bsr (a). DNA was blotted onto nitrocelulose 
membrane and hybridized with a 32P-labeled MDRI genomic probe. 
Expression level of P-glycoprotein in K562, A2-1. RI-5, K562neo. 
A2- I neo, A2-1 bsr, and RI-5bsr (b). The samples containing 10 mg of 
protein were resolved by SDS-polyacrlyamide g l electrophoresis and the 
proteins were transferred to nitrocellulose membrane. The membrane was 
probed with anti-P-glycoprotein a tibody C219. 
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Table 1 
Relative copy number of MDR1, expression of P-glyprotein and relative resistance to Adriamycin in the clones Ibr hybridization 
Cell Viability " (%) Relative copy Relative 
G418 blasticidin S number of MDR1 resistance 
Expression of 
P-glycoprotein h(%) 
K562 0 0 I I 
K562neo 94.6 0 1 I 
A2-1 0 0 32 131 
A2- I neo 98.6 0 32 136 
A2-1 bsr 0 99.3 32 149 
R1-5 0 0 26 2 
RI-5bsr 0 92.9 26 2 
<1 
<1 
100 
93 
90 
5 
5 
" Cells were incubated for 6 days in the presence of 400 /xg/ml G418 or 4 tzg/ml blasticidin S. 
Then, viability was measured by trypan blue exclusion assay. 
b Expression of P-glycoprotein was determined by immunoblot analysis using anti-P-glycoprotein antibody C219. 
in 1 ml of PBS and transferred to a disposable Bio-Rad 
cuvette (0.4-cm electrode gap). Ten micrograms of the 
plasmid was added to the suspension, and the cuvette was 
chilled for 10 min and then exposed to a single pulse (field 
strength 350 V/cm, capacitance 500 /zF) using a Bio-Rad 
gene pulsar. Following the pulse, the cells were transferred 
in the fresh complete medium and cultured for two days. 
G418-resistant clones (K562neo, A2-1 neo) were isolated 
at a concentration of 600 mg/ml  for 7 days by limiting 
dilution. Similarly, blasticidin S-resistant clones (A2-1 bsr, 
Rl-5bsr) were isolated at a concentration of 6 /xg/ml for 
6 days. 
2.5. Cell fusion 
Cell fusion was carried out using following procedure: 
1 × 106 cells were washed twice with PBS and treated 
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Fig. 2. Relative copy number of MDR1 and expression levels of P-glyco- 
protein in the revertant clones. Relative copy number of MDR1 was 
determined by DNA dot blot analysis. Expression of P-glycoprotein was 
determined by immunoblot analysis using monoclonal antibody C219. 
Open circles showed resistant clones that are > 5-fold resistant to 
Adriamycin, and closed circles showed revertant clones that are < 5-fold 
resistant. 
with the polyethylene glycol (mol. wt. 4000, Boehringer- 
Mannheim Biochemica) for 1 min. After removal of the 
fusing agent, the cells were washed three times with PBS 
and then incubated for 2 days in the complete medium. 
The fused cells were isolated at a concentration of 400 
/zg/ml G418 and 4 /zg/ml blasticidin S by limiting 
dilution. 
A 250 
A 
o~ 
200 
e t~ 
150 
& 
"6 100 
._~ 
~ 50 o.  
X 
UJ 
0 
0 
K 5 6 2 ~  I 
50 100 150 200 
Mean Channel Number 
250 
B t000 f 
b 
J ~, 100- A2-1 
"5 
~ 10- 
W . 
50 160 1~0 ~ 250 
Mean Channel Number 
Fig. 3. Seven standard clones that expressed various levels of P-glyco- 
protein were analyzed on flow cytometer using MRKI6. The expression 
level of P-glycoprotein was determined by immunoblot analysis using 
C219. Expression level of P-glycoprotein (n= 3) was plotted against 
mean channel (a) and on the exponential axis (b). 
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Table 2 
Relative copy number of MRDI and relative resistance Adriamycin in the hybrid cells 
263 
Cell Viability ' (c~) Relative copy 
G418 blasticidin S number of MDRI b 
(400 btg/ml) (4 btg/ml) 
Relative 
resistance 
K562 
A2-1 
R1-5 
K562neo × A2-1 bsr- 
A2-1 neo × RI-5bsr- 
RI-5bsr × K562neo- 
0 0 1.0 1 
0 0 32 140 
0 0 26 2.2 
1 94.4 98.5 14 13 
3 95.5 93.6 16 16 
5 89.9 94.3 20 29 
2 94.5 90.2 41 150 
3 95.5 99.6 46 120 
6 89.9 91.3 48 210 
2 96.2 92.0 8 I. 1 
4 91.1 97.2 1 I 0.89 
5 99.1 95. I 10 1.0 
Cells were incubated for 7 days in the presence of 400 /xg/ml G418 
exclusion assay. 
~' DNA content was determined [;21], and the relative copy numbers were 
or 4 ~g/ml  blasticidine S. Then. the viability was measured by trypan blue 
weighed using DNA content/cell. 
2.6. Flow cytomet~ 
Fifty microliters of cell suspension (5 × 105 cells/ml) 
were mixed with 50 /xl of 400 /zg/ml MRKI6 specific 
for P-glycoprotein monoclonal antibody and incubated at 
4°C for 30 rain. The cells 'were washed with PBS contain- 
ing 10% FCS and then incubated with 50-fold diluted 
FITC-conjugated Fab fragment to mouse IgG (Cappel 
Research Products, Durham, NC) for 30 min at 4°C. The 
cells were then washed and resuspended in PBS containing 
10% fetal calf serum and analyzed using a flow cytometer 
(Ortho). By limiting the dilution method, seven standard 
clones expressing differenl: levels of P-glycoprotein were 
obtained from K562/ADM cells which had been main- 
tained in a drug-free medium for 3 or 6 months. The 
clones were expanded and frozen in liquid nitrogen until 
needed. 
2.7. Accumulation of rhodamine123 (Rh123) 
Accumulation of Rh123 was measured, as described by 
Chaudhary and Roninson [18]. Briefly, cells (2 × 105/ml) 
were stained with 100 ng/ml Rh123 at 37°C for 2 h, 
washed two times and resuspended in cold PBS, and 
analyzed by flow cytometry. 
2.8. Adriamvcin sensiticitv 
Cells (2 × 103/50  /.d/well) were cultured for 5 h in a 
96-well plate and then 50 btl of graded concentrations of 
Adriamycin were added. After 72 h of continuous drug 
exposure, growth of the cells was measured using the XTT 
method, and ICs0 was determined [ 19]. 
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Fig. 4. Flow cytometric analysis of MDRI expression i the hybrids. Cells (5 × 105 cells/ml) were stained with MRKI6 monoclonal ntibody at 4°C for 
30 min and incubated with FITC-conjugated Fab fragment to mouse IgG for 30 min at 4°C. The cells were then analyzed on a flow cytometer (Ortho). 
264 K. Yusa et al. / Biochimica et Biophysica Acta 1269 (1995) 260-266 
3. Results 
3.1. Expression of P-glycoprotein and copy number of 
MDR1 
Compared with parental K562 cells, a MDR clone A2-1 
contained a 32-fold copy number of MDR1 DNA and 
overexpressed P-glycoprotein, while a revertant clone RI-5 
still contained a 26-fold copy number of MDRI DNA 
copies but expressed a low level of P-glycoprotein (Fig. 1). 
P-glycoprotein expression and copy number of MDRI in 
the revertants (< 5-fold resistance to Adriamycin) and the 
MDR clones were evaluated by immunoblot analysis and 
by DNA dot blot analysis, respectively (Fig. 2). The nine 
revertants contained 2- to 26-fold MDRI DNA copies but 
expressed P-glycoprotein less than 8% of that in A2-1 
cells. The nine MDR clones contained 4- to 48-fold MDR! 
DNA copies and expressed 42-145% of the P-glycoprotein 
of the A2-1 clones. In the revertant clones, expression of 
MDRI did not depend on the copy number, whereas the 
expression of P-glycoprotein i MDR clones was depen- 
dent on the copy number. These results indicated that 
decreased expression of P-glycoprotein in the revertants 
was not due just to the loss of the copy number of MDRI 
DNA. 
or bsr gene-transfected A2-1 contained the same copy 
number of MDRI DNA and expressed similar levels of 
P-glycoprotein; it was designated A2-1neo or A2-1bsr. 
R1-5 contained 26-fold MDR1 DNA copies but showed 
only 2-fold resistance to Adriamycin (Table 1). The bsr 
gene-transfected R1-5 contained the same number of gene 
copies and expressed similar levels of P-glycoprotein as in 
RI-5; it was designated Rl-5bsr. Similarly, K562neo was 
obtained by the transfection of neo gene into K562 clone. 
These cell clones were fused, and hybrid clones were 
selected using the medium containing 400 /~g/ml G418 
and 4/xg/ml  blasticidin S (Table 2). 
Flow cytometry was performed to determine P-glyco- 
protein expression on the cell surface of the individual 
hybrid cell. Monoclonal antibody MRKI6 specific for 
P-glycoprotein [10] was used for immunofluorescence 
staining. Seven standard MDR clones were analyzed (Fig. 
3). The peak channel number obtained was plotted against 
the expression level of P-glycoprotein determined by im- 
munoblot analysis (Fig. 3a). Channel number with P- 
glycoprotein level plotted on an exponential xis showed a 
linear relationship (Fig. 3b), indicating that P-glycoprotein 
expression could be evaluated by flow cytometry. From 
the standard curve, we determined the level of P-glyco- 
protein expression i  the individual hybrid cell. 
3.2. Isolation of hybrids and expression of P-glycoprotein 
We next isolated somatic cell hybrids from the rever- 
tant, MDR or K562 clone and examined expression of 
P-glycoprotein i  the hybrids. To select hybrids, genetic 
marker neo or bsr gene was introduced into K562 clone, 
MDR clone A2-1 and revertant clone R 1-5 by electropora- 
tion, and the transfected clones were selected with 600 
/zg/ml G418 or 6 p,g/ml blasticidin S (Table 1). The neo 
3.3. Expression of P-glycoprotein and MDRI copies in the 
hybrids 
K562 × A2-1 hybrids were prepared by fusion of 
K562neo with A2-1bsr. K562neo×A2-1bsr  hybrid 
clones were analyzed by flow cytometry. The results of 
one of five hybrids obtained are shown in Fig. 4. K562neo 
× A2-1bsr hybrids expressed more P-glycoprotein than 
K562neo but less than A2-1bsr. On the standard curve 
o 
0 
0 
A2-1 bsr K562neo A2-1 neo 
i t i = t i I t L i i i 
K562neo x A2-1 bsr-1 A2-1 neo x R 1-5bsr-2 
, ] _ / , \ ,  , , 
Fluorescence 
K562neo Rl°5b i~ ~ 
R 1-5bsr xK562neo-2 
Fig. 5. Accumulation of Rh123 in the hybrids. Cells were loaded with 100 ng/ml Rh123 at 37°C for 2 h and analyzed on flow cytometry. 
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Fig. 6. Dot blot hybridization analysis of DNA from hybrids. DNA was 
blotted onto nitrocellulose and hybridized with a 32p-labeled MDRI 
genomic probe. 
(Fig. 3b), the hybrids expressed 19 + 5% P-glycoprotein 
compared with A2-1 expression (Fig. 4). An Rh123 dye 
efflux assay was carried out to measure the activity of 
P-glycoprotein expressed on the cell surface of the hybrids 
(Fig. 5). The accumulation level of Rh123 in K562neo × 
A2-1 bsr hybrids was between the level found in K562neo 
and A2-1 bsr, indicating that drug transporting activity in 
the hybrids were paralleled with P-glycoprotein expres- 
sion. The hybrids showed 14- to 20-fold resistance to 
Adriamycin, whereas A2-1 showed 140-fold resistance 
(Table 2). DNA dot blot hybridization analysis was per- 
formed to determine the MDRI copy number in the hy- 
brids (Fig. 6). Relative DNA copy number was weighed 
using DNA content/cell and was compared with the ex- 
pression level of P-glycoprotein shown in Fig. 7. The 
hybrids contained 10-fold MDRI copies (n = 5) on aver- 
age, and expression level of P-glycoprotein the hybrids 
was consistent with the copy number of MDRI. 
Similarly A2-1 x R1-5 hybrids are obtained by fusion 
of A2-1bsr with R1-5neo. One of six hybrids obtained 
were shown in Fig. 4. Mean expression level of P-glyco- 
protein and mean copy number of MDRI in six hybrids 
are shown in Fig. 7. The hybrids expressed 136 ___ 15% of 
P-glycoprotein expression compared with A2-1, indicating 
that introduction of 'silent' MDR1 DNA copies from 
Rl-5bsr into A2-1 neo resulted in an increase of P-glyco- 
protein expression. The hybrids contained 45-fold MDR1 
copies (n = 6) on average, and expression level of P- 
glycoprotein in the hybrids was consistent with the copy 
number of MDRI. Decreased accumulation of Rh123 in 
the hybrids was comparable to, but not lower than, that in 
A2- I neo (Fig. 5). The A2-1 neo × R l-5bsr hybrids howed 
120- to 210-fold relative resistance to Adriamycin (Table 
2). 
Expression of P-glycoprotein in R1-5bsrX K562neo 
hybrids was compared with K562neo or R1-5bsr (Fig. 4). 
Compared with R1-5bsr, there was no detectable increase 
of P-glycoprotein expression, no decrease of Rh123 accu- 
mulation, and no increase of Adriamycin resistance in 
R1-5bsr X K562neo, but the hybrids contained 8- to 11- 
200- 
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Fig. 7. Expression level of P-glycoprotein and relative copy number of MDRI in the hybrids. Expression of P-glycoprotein the hybrids was examined by 
flow cytometry using MRK16 monoclonal antibody. Expression level was determined by standard curve (Fig. 3b). DNA content was determined as 
described previously [22], and the relative copy number were weighed using DNA content/cell. 
266 K. Yusa et al. / Biochimica et Biophysica Acta 1269 (1995) 260-266 
fold MDRI copies. These results indicated that the MDRI 
gene in the revertant clone was not activated by cell fusion 
with the sensitive clone. 
4. Discussion 
Instability of the amplified genes in somatic hybrids has 
been reported by Hoffee et al. [20]. When hybrids were 
formed between an adenosine deaminase-amplified cell 
line and a nonamplified cell line, a rapid loss of the gene 
sequences was observed. Similar results were seen in the 
present experiment. A2-1neo × R1-5bsr -3, which ex- 
pressed 145% P-glycoprotein of A2-1neo and contained 
46-fold MDRI copies (Fig. 4, Table 2), lost more than 
70% of P-glycoprotein expression and MDRI copies after 
incubation in drug-free medium for 60 days (data not 
shown). After cell fusion, it took 14-16 days to obtain 
hybrid clones. Therefore, it was important to evaluate the 
expression level of P-glycoprotein without delay. Flow 
cytometry was a good method to examine P-glycoprotein 
expression on the cell surface. By determining the expres- 
sion level of P-glycoprotein in a series of MDR clones 
expressing different level of P-glycoprotein, we could 
quantitatively evaluate the expression level of P-glyco- 
protein on the cell surface of the hybrids using flow 
cytometry. Ling and Baker [14] found that the multidrug- 
resistant phenotype was incompletely dominant in mul- 
tidrug-resistant X drug-sensitive CHO cell hybrids, deter- 
mined by measurement of drug sensitivities. These results 
may also be due to instability of MDRI DNA copies in the 
hybrids of CHO cells. 
Revertants isolated from MDR K562/ADM cells con- 
tained multiple MDR1 copies but showed marked de- 
creased expression of P-glycoprotein. It should be noted 
that compared with A2-1neo there was increased expres- 
sion level of P-glycoprotein in the A2-1neoXR1-5bsr  
hybrids (Fig. 4). In the hybrids, 36_+ 15% increase of 
P-glycoprotein expression was observed as compared with 
A2-1 expression (Fig. 7). These results indicated that the 
'silent' MDR1 genes derived from RI-5bsr were reacti- 
vated in the hybrids. RI -5bsrX  K562neo hybrids were 
found to contain 8- to 11-fold MDRI copies (Table 2), but 
there was no increase of P-glycoprotein expression com- 
pared with RI-5bsr (Fig. 4), indicating that hybridization 
of RI-5 with K562 could not activate multiple MDRI 
genes from R1-5 clone. Chaudhary and Roninson found 
that treatment of K562 with antitumor agents, including 
Adriamycin, induced a low level of P-glycoprotein shown 
by flow cytometry, and by RT-PCR in a subpopulation of 
the treated cells. Adriamycin-induced MDR1 expression 
was maintained for at least 7 weeks after the drug was 
removed [21]. The revertants were isolated from 
K562/ADM cells established by continuous treatment with 
Adriamycin. Although the mechanism of decreased expres- 
sion of P-glycoprotein in the revertants remains to be 
elucidated, the revertants may lose a similar activation 
mechanism of MDRI stimulated by treatment with the 
antitumor agents. 
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